ARGX - ARGENX SE
805.38
-29.070 -3.609%
Share volume: 270,173
Last Updated: 04-21-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.21%
PREVIOUS CLOSE
CHG
CHG%
$834.45
-29.07
-0.03%
Fundamental analysis
0%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
0%
Performance
5 Days
-5.14%
1 Month
18.12%
3 Months
-2.62%
6 Months
-1.08%
1 Year
34.26%
2 Year
29.27%
Key data
Stock price
$805.38
DAY RANGE
$800.85 - $820.08
52 WEEK RANGE
$510.06 - $934.62
52 WEEK CHANGE
$35.44
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
07-24-2025
Company detail
CEO: Tim v. Hauwermeiren
Region: US
Website: argenx.com
Employees: 650
IPO year: 2017
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: argenx.com
Employees: 650
IPO year: 2017
Issue type:
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases. Its lead product candidate is efgartigimod for the. treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy. The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS.
Recent news